Helpdesk

Sales contact

Home > Resources > How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

How Kayentis reduces the CO2 emissions of your eCOA projects with its carbon neutral program

Last updated: October 24, 2025

In 2020, we implemented a carbon neutral program for all our clinical trials.
Our goal? To reduce project CO2 emissions without impacting cost, quality or timelines.

Subscribe to our newsletter

How Kayentis Delivered eCOA Go-Live in Just 5 Weeks for...

Turning endpoint noise into reliable CNS trial data

Kayentis publishes its first ESG report, strengthening its commitment to...

Kayentis launches interactive eConsent solution to simplify and improve patient...

Better Raters, Smarter eCOA, Stronger Data

Strengthening Endpoint Reliability: An Interview with Estelle Haenel, Chief Medical...

About the author

Marc Chaperon

Estelle brings 20+ years of experience in pre-clinical and clinical research from Top 5 Pharma and Biotech firms. Leading projects across Phases 1 to 4 in diverse therapeutic areas, she offers deep insights into clinical science, operations, and regulatory intricacies. Appointed as Chief Medical Officer at Kayentis in May 2019.

Meet us at the following events

ISOQOL 2026

18-21 OCT 2026 • Prague, Czech Republic

33rd Annual Conference | ISOQOL

CTAD Clinical Trial on Alzheimer’s Disesases

16-19 NOV 2026 • Boston, MA, USA

Meet our colleague Anna Dudalyan at CTAD. Schedule a meeting